Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 16/20 | 1.00 |
| ▸ | DBF4 | Q9UBU7 | 14/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 0.51 |
| ▸ | CDK2 | P24941 | 3/20 | 0.51 |
| ▸ | CDK9 | P50750 | 3/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528466 | 0.90 | CDC7 (0.82) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL2530828 | 0.90 | CDC7 (0.82) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL2528660 | 0.89 | CDC7 (1.00) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL2527526 | 0.86 | CDC7 (0.77) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL2526469 | 0.86 | CDC7 (1.00) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL2525002 | 0.76 | CDC7 (0.76) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL2527512 | 0.75 | CDC7 (1.00) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL2534174 | 0.74 | CDC7 (0.98) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL2530245 | 0.74 | CDC7 (1.00) | CDC7DBF4RETCDK2CDK9 | |
| SCHEMBL1049987 | 0.74 | CDC7 (1.00) | CDC7DBF4RETCDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181246-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-20140357616-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-12-04 | — | — | US | claimed |
| EP-2560971-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | claimed |
| WO-2011133388-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | claimed |
| US-20110257152-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | US | claimed |
| US-9181246-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140357616-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8822446-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2014-09-02 | — | — | US | disclosed |
| CN-103003274-A | Pyrrolopyridine inhibitors of kinases | ABBVIE INC | 2013-03-27 | — | — | CN | disclosed |
| EP-2560971-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133388-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257152-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357616-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | CDC7 1/4885DBF4 2301/4885RET 357/4885 |
| US-20110257152-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | CDC7 1/4885DBF4 2301/4885RET 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.